comparemela.com

Latest Breaking News On - Cardiovascular research technologies - Page 4 : comparemela.com

In Early Days, Bioabsorbable Stent Rivals Nonabsorbable Devices

Late lumen loss with a new bioabsorbable drug-eluting stent is on par with nonabsorbable devices in early data.

Germany
Munich
Bayern
German
Michaelh-joner
Aokev-finn
Michael-haude
University-of-maryland
Philips
German-center
Cvpath-institute
Heart-vascular-center

Long-Term BP Reductions With Renal Denervation Not Race Specific

Long-term blood pressure reductions in the Black patient cohort of the SYMPLICITY HTN-3 renal denervation trial challenge early results.

New-york
United-states
Bangalore
Karnataka
India
Washington
New-york-university
Deepakl-bhatt
Amgen
Pfizer
Cardiovascular-research-technologies

At 5 Years, TAVI Valves Perform Better Than Surgical Ones

Risk for Stent Infection Low but May Be Underreported

Renal denervation lowers BP in Black patients with resistant hypertension at 3 years

In Black patients with resistant hypertension, renal denervation was associated with reductions in systolic BP at 3 years, according to new data from the SYMPLICITY HTN-3 trial. As Healio previously reported, in the main results of SYMPLICITY HTN-3, the renal denervation system (Symplicity, Medtronic) did not significantly lower office systolic BP at 6 months compared with a sham procedure.

United-states
Washington
Richard-smith
Byerik-swain
Deepakl-bhatt
Cardiovascular-research-technologies
Icahn-school-of-medicine-at-mount-sinai
Medtronic
Breaking-trials
Today-intervention-section-editor-deepak
Mount-sinai-heart
Valentin-fuster-professor

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.